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Abstract. Quantitative polymerase chain reaction (qPCR) 
is a method of amplifying and detecting small samples of 
genetic material in real time and is in routine use across many 
laboratories. Speed and thermal uniformity, two important 
factors in a qPCR test, are in direct conflict with one another 
in conventional peltier-driven thermal cyclers. To overcome 
this, companies are developing novel thermal systems for 
qPCR testing. More recently, qPCR technology has developed 
to enable its use in point-of-care testing (POCT), where the 
test is administered and results are obtained in a single visit 
to a health provider, particularly in developing countries. For 
a system to be suitable for POCT it must be rapid and reliable. 
In the present study, the speed and thermal uniformity of four 
qPCR thermal cyclers currently available were compared, two 
of which use the conventional peltier/block heating method 
and two of which use novel heating and cooling methods.
Introduction
Quantitative polymerase chain reaction (qPCR), the method by 
which a small sample of genetic material can be exponentially 
amplified and quantitatively measured in real time, is now a 
mainstay of research and medical laboratories. As the process 
has evolved, the applications for qPCR have increased rapidly, 
and include the detection of infectious diseases, paternity 
identification, forensic analysis and food processing. The PCR 
process necessitates the cycling of test samples through a 
temperature profile, typically 95, 55 and 72˚C, multiple times. 
The time taken to change the temperature of the samples 
between these levels is a key determinant of the speed of the 
process and thus of the duration of a test (1). A typical 40-cycle 
PCR can take ~2 h to complete and improvements in that time 
have not been achieved as rapidly as the advances in other 
areas. Therefore, some of the potential benefits of the qPCR 
process remain limited by speed.
Thermal uniformity, the absence of which can cause 
discrepancies in the cycling conditions between different 
samples on the same plate, is directly linked to speed. In many 
PCR instruments, conductive blocks are used to connect the 
heating or cooling source(s) to the test samples. When heating 
and cooling the system, it is necessary to drive heat into and 
out of the block. Temperature gradients are eliminated by the 
natural flow of heat within the blocks; therefore, over time the 
same conditions should be delivered to all the test samples. 
However, block-based systems are vulnerable to greater heat 
losses on the edges and surfaces that tend to distort the thermal 
distribution. The conductivity of the blocks affects the rate of 
heat flow and thus the uniformity of heating of the samples. In 
addition, the larger the thermal mass of the block, the greater 
the amount of heat to be transferred and the longer this will 
take. The faster heat is driven into or out of the system, the 
less time is available for the temperature distribution of the 
conductive block to even out and for thermal uniformity to 
be maintained. Ultimately, such a system can only maintain 
thermal uniformity if the rate of change of temperature is 
slower than the time it takes for the temperature of the conduc-
tive block to even out. To achieve quick cycle times, large 
temperature gradients are applied to the block, which can lead 
to the target temperatures of samples being over- or undershot. 
Thus, in these types of systems, the requirement for uniformity 
of temperature directly conflicts with the desire for speed; they 
are able to deliver one feature or the other but not both (2).
The ABI Prism 7900HT (Applied Biosystems, Thermo 
Fisher Scientific, Waltham, MA, USA) is perhaps the industry 
standard peltier/block‑based thermal cycler. The CFX96 
(Bio-Rad Laboratories, Inc., Hercules, CA, USA) provided an 
upgrade to the conventional system by reducing the thermal 
mass of the block. Alternatives to the block-based system have 
also been developed. The Rotor-Gene Q (Qiagen, Hilden, 
Germany) combines a centrifugal set-up with an air-based 
thermal system. Ensuring that samples are continuously 
rotated through heated air removes the edge effect to provide 
superior thermal uniformity. xxpress® (BJS Biotechnologies, 
Perivale, UK) employs a different system in which an ‘active 
heating’ method is combined with a block of low thermal 
mass, precisely controlling the amount and location of addi-
tional heating to avoid temperature discrepancies (Table I). 
The present study investigated and compared the efficiency 
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and thermal uniformity of four of the qPCR thermal cyclers 
currently available that use the conventional block/peltier 
system or novel methods.
Materials and methods
qPCR. The expression of 18S rRNA in human genomic DNA 
was assessed and compared by qPCR using an ABI Prism 
7900HT, a Bio‑Rad CFX96 System, a Qiagen Rotor‑Gene Q 
and a BJS Biotechnologies xxpress®. Human genomic DNA 
was purchased from Bioline (Meridian Bioscience, Cincinnati, 
OH, USA) and input in concentrations of 100, 10, 1, 0.1 and 
0.01 ng/µl to give final concentrations of 5, 0.5, 0.05, 0.005 
and 0.0005 ng/µl, generating a standard curve. Eukaryotic 
18S rRNA gene primers were used as follows: forward, 
3'-AAACGGCTACCACATCCAAG‑5' and reverse, 3'‑CCTC-
CAATGGATCCTCGTTA‑5'. SYBR FAST qPCR master mix 
(Kapa Biosystems, Wilmington, MA, USA) was used across 
all platforms using the following thermal profile: 20 sec hot 
start at 95˚C followed by 40 cycles of 95˚C for 1 sec and 60˚C 
for 10 sec. Heating and cooling rates and all other parameters 
were at the manufacturers' pre-set levels.
Thermal variability was assessed in qPCR by measuring 
the amplification of 18S rRNA in a selection of wells 
covering all areas of the sample plate on ABI Prism 7900HT, 
Bio‑Rad CFX96 System, Qiagen Rotor‑Gene Q and BJS 
Biotechnologies xxpress instruments. Human genomic DNA 
at 100 ng/µl (final concentration, 5 ng/µl) was used with the 
protocol detailed above.
Statistical analysis. Statistical tests commonly used to 
determine the reliability and accuracy of a quantitative PCR 
assay include performing a standard curve experiment with 
each dilution series run in triplicate. The Cq value was plotted 
against the log of the nucleic acid input level to generate a 
linear graph. The slope or gradient of this graph was used to 
determine the PCR reaction efficiency and a linear regression 
analysis with a correlation coefficient or R2 value was included 
to determine the accuracy and repeatability of the standard 
curve. The ideal result is a PCR reaction efficiency of 100% 
and an R2 value of 1. An efficiency of <90 or ≥110% is unac-
ceptable and indicates that further optimisation is required. If 
the R2 value is ≤0.985, this raises questions about assay reli-
ability with respect to pipetting accuracy and the range of the 
assay (3).
Results
Amplification efficiency. A standard curve was generated by 
amplifying 18S rRNA in human genomic DNA at concentra-
tions of 5, 0.5, 0.05, 0.005 and 0.0005 ng/µl and plotting Ct 
against log concentration. Efficiency was calculated by the 
following equation: Efficiency = 10(-1/slope)-1. Efficiency of reac-
tion values between 90 and 110% are considered acceptable 
for qPCR reactions. The fastest instrument was the xxpress®, 
which completed 40 cycles in 12 min (Fig. 1).
Thermal variability. Thermal variability was assessed by 
measuring the amplification of 18S rRNA in 5 ng/µl human 
genomic DNA in a selection of wells covering all areas of the 
sample plate on ABI Prism 7900HT, Bio‑Rad CFX96 System, 
Qiagen Rotor-Gene Q and BJS Biotechnologies xxpress 
instruments (Fig. 2). The average Ct, Ct spread and Ct standard 
deviation were for CFX: 16.0, 1.315 and 0.34; for xxpress: 13.6, 
1.2 and 0.29; for Prism 7900HT: 14.4, 4.526, and 1.91; and for 
Rotor‑Gene: 16.8, 1.319, and 0.43 (Fig. 3).
Discussion
qPCR instrumentation is rapidly evolving not only to meet 
the needs of basic science but also in an attempt to address 
some of the needs of the current healthcare system, in 
terms of diagnosis as well as prognosis. For example, qPCR 
technology has been widely used in the field of molecular 
diagnostics for a number of infectious diseases (4). Food 
and Drug Administration-approved qPCR-based screening 
tests include group A Streptococcus and methicillin-resistant 
Staphylococcus aureus (MRSA), HIV-1, human metapneumo-
virus and H1N1 influenza virus (5,6). More recently, Qiagen 
received FDA approval of a therascreen® KRAS RGQ PCR 
kit, paired with a colorectal cancer drug. KRAS mutations 
occur in ~40% of colorectal cancer patients (7,8). Therefore, 
screening patients by PCR will detect the most frequent muta-
tions in the KRAS gene and should aid with the selection of 
therapeutic interventions.
Over the past decade, there has been a shift from testing in 
reference hospitals/centres to clinical/diagnostic laboratories 
worldwide (4). Point of care testing (POCT) allows a test to be 
carried out and results obtained in a single visit to a primary 
or secondary care health provider (9). In developing countries, 
POCT is perhaps even more effective. The requirement for 
Table I. Ramp rate and thermal uniformity of qPCR instruments.
qPCR platform Thermal system Advertised fastest ramp rate (˚C/sec) Advertised thermal uniformity (˚C)
ABI Prism 7900HT Block/peltier 1.5 ±0.5 (measured 30 sec after
   timing starts)
Bio‑Rad CFX96 Block/peltier 3.3 (average) ±0.4 (well‑to‑well within
   10 sec of reaching 90˚C)
Qiagen Rotor‑Gene Q Air 15 (peak) ±0.02
BJS biotechnologies xxpress® Resistive heating 10 ±0.3
qPCR, quantitative polymerase chain reaction.
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Figure 1. Amplification efficiency of four qPCR instruments.
Figure 2. Thermal variability upon amplification of 18s rRNA using 5 ng/µl human genomic DNA. (A) CFX96, (B) xxpress®, (C) ABI Prism 7900HT and 
(D) Rotor-Gene Q.
Figure 3. Average Ct of all instruments.
  A   B
  C   D
Figure 4. Current and future applications of qPCR testing. CTCs, circulating 
tumour cells; SNPs, single nucleotide polymorphisms; TDM, therapeutic 
drug monitoring; miRNA, microRNA.
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expensive, central laboratories, highly trained technicians 
and a reliable method of specimen and data transport can 
all be removed with the implementation of a well-designed, 
multifunctional POCT system. Bringing the test into the clinic 
allows treatment to commence without delay and, in areas of 
high displacement, reduces the likelihood of losing patient 
contact before the condition has been effectively treated. This 
is particularly important for communicable diseases such as 
HIV/AIDS, measles and typhoid fever (10). An effective POC 
test in a low resource setting is inexpensive to use and main-
tain. The test must be easy to operate, requiring little to no 
training or specialist knowledge to both generate and interpret 
results. In a recent study of sub‑Saharan Africa, only 34% 
of hospitals had reliable electricity access (11). Since energy 
access for healthcare facilities in this region varies markedly, 
and as electrical sources may be unreliable, low electrical 
consumption or even the ability to run on battery or solar 
power is desirable.
The results of the present study demonstrate that the 
performance of new technologies in qPCR instrumentation 
such as Rotor-Gene Q and xxpress, is equally as good as, 
or even better than, that of conventional qPCR instruments, 
in terms of amplification efficiency and thermal uniformity. 
However, a major advantage is that this instrument can deliver 
40‑cycle qPCR in <10 min. Rapid testing can be lifesaving. For 
example, rapid diagnostic tests can help in the diagnosis and 
management of patients who present with signs and symptoms 
compatible with influenza. These technologies can cut down 
the time from 3-10 days for conventional viral cell cultures to 
less than minutes (12). Infections with MRSA are known to 
be associated with considerable morbidity and mortality (13). 
Current sample preparation/testing times based on blood 
samples can take up to 5 h. However, in an emergency situation 
this process might be too long if the patient admitted is posi-
tive for MRSA and therefore has the potential to infect others. 
Equally, an early diagnosis of tuberculosis will assist not only 
in the initiation of appropriate treatment but also limit the 
spread of this highly contagious disease (14). A test that could 
be administered either at admission to the clinic, or even in an 
ambulance on the way to the hospital, and takes only 10 min 
could be of real benefit. Moreover, given the unreliability of 
electricity in the developing world, diagnostic instrumentation 
that is rapid is vital.
To date, qPCR-based diagnosis is often associated with 
high cost, time-consuming procedures, scientists and clinicians 
trained in qPCR analysis, lack of specificity and sensitivity or 
even standardisation for certain tests. In the future (Fig. 4), 
a standardised, rapid, scalable, affordable and easy-to-use 
qPCR platform for use in POCT should provide an invalu-
able platform in the field of diagnostic/prognostic testing that 
will complement the current conventional methods, including 
microscopy, cell culture and immunological-based methods.
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